Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: Rationale and design of the OVERCOME trial

Journal of Cardiac Failure

Volumn 17, Issue 8, 2011, Pages 643-648

  Bosch, Xavier ^a,c   Esteve, Jordi ^a,c   Sitges, Marta ^a,c   De Caralt, Teresa M ^a   Domènech, Ariadna ^a   Ortiz, José T ^a,c   Monzó, Mariano ^b,c   Morales Ruiz, Manuel ^a,c   Perea, Rosario J ^a   Rovira, Montserrat ^a,c  

^a HOSPITAL CLÍNIC   (Spain)

^b Physiology Section   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiotoxicity; carvedilol; chemotherapy; enalapril; prevention; ventricular dysfunction

Indexed keywords

ANTINEOPLASTIC AGENT; CARVEDILOL; ENALAPRIL;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBAZOLES; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; SAMPLE SIZE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 79961004271     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2011.03.008     Document Type: Article

References (35)

1. Travis LB, Rabkin CS, Morris Brown L, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25. (Pubitemid 43057089)
2. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31.
3. Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, et al. Four versus six courses of dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer 2006;106:136-45. (Pubitemid 43032558)
4. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58. (Pubitemid 46929299)
5. Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005;131: 561-78. (Pubitemid 43899624)
6. de Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, et al. Anthracycline cardyomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2009;121:276-92.
7. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 2010;121:675-83.
8. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22:3700-4. (Pubitemid 41095209)
9. Kuittinen T, Jantunen E, Vanninnen E, Mussalo H, Vuolteenaho O, Ala-Kopsala M, et al. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol 2006;77: 120-7.
10. Chung T, Lim W-C, Sy R, Cunningham I, Trotman J, Kritharides L. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart 2008;94:911-8. (Pubitemid 351914704)
11. García-Alvarez A, García-Albéniz X, Esteve J, Rovira M, Bosch X. Cardiotoxicity of tyrosine-kinase-targeting drugs. Cardiovasc Hematol Agents Med Chem 2010;8:11-21.
12. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864-71. (Pubitemid 41095177)
13. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, et al. Subclinical anthracycline and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701-7.
14. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;(2):CD003917.
15. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685-91.
16. Yusuf S, Sleight P, Pogue J, Dagenais G, Montague T, Bosch J, et al, Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzime inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
17. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al, SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
18. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al, Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6. (Pubitemid 26001955)
19. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, de Giacomi G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20.
20. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001;414:71-8. (Pubitemid 32174877)
21. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001;21:469-73. (Pubitemid 33130747)
22. Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ, Cunningham JN, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002;4:583-6. (Pubitemid 35278509)
23. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-risk chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81. (Pubitemid 44901520)
24. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492-8. (Pubitemid 41691573)
25. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
26. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
27. Packer M, Cotas AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. (Pubitemid 32479962)
28. Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001;357:1385-90.
29. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 2001;19:152-71. (Pubitemid 32703323)
30. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185:218-27. (Pubitemid 36062795)
31. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37:837-46. (Pubitemid 39222076)
32. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62. (Pubitemid 44855419)
33. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al, SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 1997;29:229-36. (Pubitemid 27059948)
34. Eschenhagen T, Force T, Ewer MS, Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:1-10.
35. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008. (Pubitemid 47477279)